| Design and endpoints of clinical trials in hepatocellular carcinoma JM Llovet, AM Di Bisceglie, J Bruix, BS Kramer, R Lencioni, AX Zhu, ... Journal of the National Cancer Institute 100 (10), 698-711, 2008 | 1725 | 2008 |
| Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model LWD Weber, M Boll, A Stampfl Critical reviews in toxicology 33 (2), 105-136, 2003 | 1642 | 2003 |
| Mechanisms of hepatotoxicity H Jaeschke, GJ Gores, AI Cederbaum, JA Hinson, D Pessayre, ... Toxicological sciences 65 (2), 166-176, 2002 | 1470 | 2002 |
| Diagnosis and management of primary sclerosing cholangitis. R Chapman, J Fevery, A Kalloo, DM Nagorney, KM Boberg, B Shneider, ... Hepatology (Baltimore, Md.) 51 (2), 660, 2010 | 1073 | 2010 |
| Biliary tract cancers PC De Groen, GJ Gores, NF LaRusso, LL Gunderson, DM Nagorney New England Journal of Medicine 341 (18), 1368-1378, 1999 | 1073 | 1999 |
| Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis AE Feldstein, A Canbay, P Angulo, M Taniai, LJ Burgart, KD Lindor, ... Gastroenterology 125 (2), 437-443, 2003 | 1014 | 2003 |
| Hepatocellular carcinoma: clinical frontiers and perspectives J Bruix, GJ Gores, V Mazzaferro Gut 63 (5), 844-855, 2014 | 979 | 2014 |
| mir-29 regulates Mcl-1 protein expression and apoptosis JL Mott, S Kobayashi, SF Bronk, GJ Gores Oncogene 26 (42), 6133-6140, 2007 | 938 | 2007 |
| Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway AE Feldstein, NW Werneburg, A Canbay, ME Guicciardi, SF Bronk, ... Hepatology 40 (1), 185-194, 2004 | 892 | 2004 |
| Cholangiocarcinoma N Razumilava, GJ Gores The Lancet 383 (9935), 2168-2179, 2014 | 805 | 2014 |
| Cathepsin B contributes to TNF-α–mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c ME Guicciardi, J Deussing, H Miyoshi, SF Bronk, PA Svingen, C Peters, ... The Journal of clinical investigation 106 (9), 1127-1137, 2000 | 803 | 2000 |
| Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report PA Clavien, M Lesurtel, PMM Bossuyt, GJ Gores, B Langer, A Perrier The lancet oncology 13 (1), e11-e22, 2012 | 792 | 2012 |
| Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: a pilot study J Laurin, KD Lindor, JS Crippin, A Gossard, GJ Gores, J Ludwig, J Rakela, ... Hepatology 23 (6), 1464-1467, 1996 | 790 | 1996 |
| Apoptosis and necrosis in the liver: a tale of two deaths? H Malhi, GJ Gores, JJ Lemasters Hepatology 43 (S1), S31-S44, 2006 | 763 | 2006 |
| Lysosomes in cell death ME Guicciardi, M Leist, GJ Gores Oncogene 23 (16), 2881-2890, 2004 | 719 | 2004 |
| Pathogenesis, diagnosis, and management of cholangiocarcinoma S Rizvi, GJ Gores Gastroenterology 145 (6), 1215-1229, 2013 | 691 | 2013 |
| Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism M Jaiswal, NF LaRusso, LJ Burgart, GJ Gores Cancer research 60 (1), 184-190, 2000 | 685 | 2000 |
| Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma J Bridgewater, PR Galle, SA Khan, JM Llovet, JW Park, T Patel, TM Pawlik, ... Journal of hepatology 60 (6), 1268-1289, 2014 | 671 | 2014 |
| The role of proteases during apoptosis T Patel, GJ Gores, SH Kaufmann The FASEB Journal 10 (5), 587-597, 1996 | 665 | 1996 |
| Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment B Blechacz, GJ Gores Hepatology (Baltimore, Md.) 48 (1), 308, 2008 | 664 | 2008 |
